Kimberly-Clark Acquires Kenvue
November 3, 2025
Kimberly-Clark agreed to acquire Kenvue, the Johnson & Johnson spin-off that owns Tylenol, Neutrogena, BAND-AID and other consumer health brands, in a cash-and-stock transaction valued at about $48.7 billion. The deal will combine major consumer-health and personal-care portfolios under Kimberly-Clark and is expected to generate pro forma 2025 net revenues of roughly $32 billion.
- Buyers
- Kimberly-Clark
- Targets
- Kenvue
- Industry
- Consumer Products
- Location
- New Jersey, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Alcon Acquires EYSUVIS and INVELTYS Commercial Portfolio from Kala Pharmaceuticals
May 23, 2022
Pharmaceuticals
Alcon Inc. agreed to acquire the commercial portfolio and related intellectual property for EYSUVIS and INVELTYS from Kala Pharmaceuticals for an upfront payment of $60 million, with Kala eligible for future commercial milestone payments. The asset sale allows Alcon to expand its ophthalmic drug franchises while enabling Kala to focus on its pipeline (KPI-012) and extend its cash runway.
-
Cooper Consumer Health Acquires Viatris' Over-the-Counter Business
July 3, 2024
Pharmaceuticals
Cooper Consumer Health has completed the acquisition of the Over-the-Counter (OTC) business of Viatris Inc., following regulatory approvals and worker council consultations. The deal brings more than 200 brands (including Betadine, Saugella, Armolipid and CB12), two manufacturing sites in Mérignac (France) and Confienza (Italy) and an R&D centre in Monza (Italy) into Cooper's platform, doubling Cooper's revenues to approximately €1.2bn.
-
Bristol Myers Squibb Acquires Karuna Therapeutics
December 22, 2023
Biotechnology
Bristol Myers Squibb has agreed to acquire Karuna Therapeutics for $330 per share in an all-cash transaction valued at approximately $14.0 billion (about $12.7 billion net of cash). The acquisition adds Karuna's lead neuroscience asset KarXT and its early-stage pipeline to BMS's neuroscience portfolio, accelerating capability and late-stage product expansion in psychiatric and neurodegenerative disorders.
-
Nestlé Acquires The Bountiful Company's Core Vitamin Brands for $5.75B
August 9, 2021
Food & Beverage
Nestlé (via Nestlé Health Science) agreed to acquire the core vitamin and supplement brands of The Bountiful Company from KKR and Carlyle for $5.75 billion, integrating brands such as Nature's Bounty, Solgar, Puritan's Pride and Osteo Bi‑Flex into its NHSc portfolio. The deal (expected/closed in H2 2021) brings roughly 4,000–4,500 employees into Nestlé Health Science and establishes Nestlé as a global leader in vitamins, minerals and nutritional supplements across mass retail, specialty retail and e‑commerce.
-
Fresenius Kabi Acquires Ivenix
March 31, 2022
Medical Devices
Ivenix, Inc. has entered into a definitive agreement to be acquired by Fresenius Kabi for an upfront payment of $240 million plus additional milestone payments. The deal brings Ivenix's next-generation infusion pump technology and software together with Fresenius Kabi's IV fluids and infusion therapy portfolio to create a comprehensive infusion offering and accelerate U.S. commercial expansion.
-
Cinven Acquires Bayer Environmental Science Professional (Envu)
March 10, 2022
Environmental Services
International private equity firm Cinven has acquired Bayer's Environmental Science Professional business for $2.6 billion. The carved-out business, headquartered in Cary, North Carolina and operating as Envu with nearly 900 employees, will run as an independent platform focused on pest management, vector control and vegetation management while Bayer uses proceeds to reduce net debt.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.